不同剂量尿激酶静脉溶栓治疗脑梗死疗效与安全性分析.docVIP

不同剂量尿激酶静脉溶栓治疗脑梗死疗效与安全性分析 　　[摘要] 目的 探?不同剂量尿激酶静脉溶栓治疗脑梗死的临床疗效和安全性。方法 方便选取于该院2011年1月―2016年5月收治的脑梗死患者122例为研究对象，依据尿激酶应用剂量随机分组，其中A组（n=62）应用剂量为中剂量（100万IU），B组（n=60）应用剂量为大剂量（150万IU），比较两组临床疗效。 结果 A组总有效率为85.4%，B组为83.3%，对比差异无统计学意义（P0.05）。A组和B组治疗前神经功能缺损评分分别为（16.42±3.74）分和（16.36±3.52）分，差异无统计学意义（P0.05）；A组和B组治疗后24 h后神经功能缺损评分分别为（7.33±1.73）分和（7.24±1.67）分，差异无统计学意义（P0.05）；在治疗后7 d神经功能缺损评分同样差异无统计学意义（P0.05）。A组与B组治疗后90 d Barthel指数分别为（75.99±19.78）和（74.92±19.18），差异无统计学意义（P0.05）；Rankin评分分别为（2.63±0.57）分和（2.73±0.55）分，差异无统计学意义（P0.05）。药物安全性：A组不良事件发生率为3.2%，明显低于B组16.6%，对比差异有统计学意义（P0.05）。结论 相较于大剂量（150万IU）尿激酶，中剂量（100万IU）尿激酶静脉溶栓治疗脑梗死的疗效相当，但安全性更高，值得推广。 　　[关键词] 尿激酶；静脉溶栓治疗；脑梗死 　　[中图分类号] R743 [文献标识码] A [文章编号] 1674-0742（2016）12（b）-0115-04 　　Efficacy and Safety of Intravenous Thrombolysis with Different doses of Urokinase in the Treatment of Cerebral Infarction 　　YANG Lin-song 　　Department of Neurology， Hanjiang Hospital， Putian City， Putian，Fujian Province， 351111 China 　　[Abstract] Objective To investigate the clinical efficacy and safety of intravenous thrombolysis with different doses of urokinase in the treatment of cerebral infarction. Methods Convenient selection a total of 122 patients with cerebral infarction admitted in our hospital from January 2011 to May 2016 were randomly divided into two groups according to the application dose of urokinase. The dose of group A（n = 62） was 1 million IU，the group B n = 60） were treated with high dose （1.5 million IU）. The clinical efficacy was compared between the two groups. Results The total effective rate was 85.4% in group A and 83.3% in group B. In group A and group B， the scores of neurological deficits （16.42 ± 3.74）points and （16.36 ± 3.52）points were not significantly different （P 0.05） The neurological deficit scores （7.33 ± 1.73）points and （7.24 ± 1.67）points， respectively， were not significantly different （P 0.05）； neurological deficit scores at 7 days after treatment given critical （P 0.05）. Conclusion1. The Barthel index was （75.99 ± 19.78